Novartis AG ADR buy melinda
Start price
30.07.17
/
50%
€77.06
Target price
20.09.17
€77.57
Performance (%)
0.91%
End price
20.09.17
€77.76
Summary
This prediction ended on 20.09.17 with a price of €77.76. During the runtime of the prediction for Novartis AG ADR the price only changed by 0.91%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | 1.717% | 1.717% | 25.530% | 38.435% |
| iShares Core DAX® | 0.323% | 2.208% | 21.610% | 72.184% |
| iShares Nasdaq 100 | 0.145% | -0.987% | 5.603% | 112.977% |
| iShares Nikkei 225® | 0.091% | -1.421% | 12.897% | 46.571% |
| iShares S&P 500 | 0.371% | -0.469% | 3.470% | 68.947% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Zykadia (sNDA)
FDA Entscheidung über Zykadia als First-Line - Behandlung von Patienten mit Krebs der Lunge metastasierendem nicht-kleinzelligen (NSCLC) , deren Tumoren sind anaplastic lymphatische Kinase (ALK) - positiv
2017.08.23
FDA genehmigt den erweiterten Einsatz von Zykadia 26, Mai 2017